Abstract
Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residual disease (MRD) is an important endpoint representing more accurately the depth of remission than complete response (CR), and is highly prognostic of progression-free survival (PFS) and overall survival (OS). MRD could be considered a key outcome of clinical trials and, as a surrogate for PFS, could identify the most cost-effective and durable treatment sequencing. MRD testing could also determine which patients would benefit from additional therapy and, accordingly, ascertain when therapy should be stopped earlier, to reduce toxicity and increase treatment-free intervals. Our article discusses possible uses of MRD in the modern era of CLL, including its definition, measurement, and value as a surrogate endpoint in clinical trials, and its potential roles in clinical practice.
References
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen
Mar 16, 2007·Leukemia·A C RawstronP Hillmen
Jul 28, 2007·Leukemia·R M de TuteA C Rawstron
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesc BoschEmili Montserrat
Apr 16, 2008·Blood·Constantine S TamMichael J Keating
Nov 20, 2008·British Journal of Haematology·Carmen D SchweighoferClemens-Martin Wendtner
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole LamannaMark A Weiss
Apr 3, 2009·Annals of Hematology·Karim MaloumHélène Merle-Béral
Jul 21, 2010·Developmental Cell·Daniel J Klionsky
Oct 5, 2010·Lancet·M HallekUNKNOWN German Chronic Lymphocytic Leukaemia Study Group
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
Apr 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew R PettittPeter Hillmen
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Oct 9, 2012·Leukemia·A C RawstronUNKNOWN European Research Initiative in CLL
Feb 20, 2013·Leukemia·A C LoganD B Miklos
Oct 15, 2013·Blood·Pau AbrisquetaFrancesc Bosch
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Apr 5, 2014·Haematologica·Rodrigo SantacruzJulio Delgado
Apr 8, 2014·Blood·Paolo StratiWilliam G Wierda
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Jan 24, 2015·Blood Cancer Journal·T W FarrenS G Agrawal
May 23, 2015·Blood·Jacques J M van DongenAlberto Orfao
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Committee
Sep 4, 2015·European Journal of Haematology·Paula CramerMichael Hallek
Oct 22, 2015·Blood·Kirsten FischerMichael Hallek
Oct 24, 2015·Blood·Philip A ThompsonMichael J Keating
Nov 19, 2015·Blood·Philip A Thompson, William G Wierda
Dec 8, 2015·Leukemia·A C RawstronP Ghia
Aug 31, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabor KovacsSebastian Böttcher
Aug 31, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G Wierda
Oct 5, 2016·Blood·Marwan KwokPeter Hillmen
Dec 17, 2016·OncoTargets and Therapy·Simona SerratìRosamaria Pinto
Dec 30, 2016·British Journal of Haematology·Abraham M VargheseUNKNOWN NCRI CLL Sub-Group
Citations
Nov 21, 2018·Blood·Anton W LangerakJacques J M van Dongen
Nov 2, 2019·Bone Marrow Transplantation·Megan OthusRoland B Walter
Aug 29, 2019·Leukemia·Francesc BoschVéronique Leblond
Jan 17, 2020·HemaSphere·Moritz FürstenauMichael Hallek
Apr 26, 2020·International Journal of Laboratory Hematology·Alba MoraCarol Moreno
Dec 7, 2019·Hematology·Jacqueline CloosRichard Dillon
Dec 15, 2018·Cytometry. Part B, Clinical Cytometry·Adam C SeegmillerFiona E Craig
Jun 2, 2020·Clinical Case Reports·Ramya MuddasaniMarc Braunstein
May 23, 2021·Leukemia & Lymphoma·Alexandre BazinetNathalie A Johnson